CAMBRIDGE, Mass., April 24, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1.
Mestag Therapeutics Ltd.: Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
RESEARCHERS at Navarra's Cima University believe that a new combination of immunotherapy treatment could be used to fight liver cancer, and are testing
Spanish researchers at Cima University of Navarra have developed a new immunotherapy combination that improves efficacy in animal models of hepatocellular carcinoma. This is a proof of concept that lays the foundations for the application of this treatment in patients with the most common liver cancer.